| Drug Name: | Bosentan (147536-97-8) |
|---|---|
| PubChem ID: | 104865 |
| SMILES: | CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC |
| InchiKey: | GJPICJJJRGTNOD-UHFFFAOYSA-N |
| Therapeutic Category: | Antihypertensive Agents, Cardiovascular Agents |
| Molecular Weight (dalton) | : | 551.625 |
| LogP | : | 4.2039 |
| Ring Count | : | 4 |
| Hydrogen Bond Acceptor Count | : | 10 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 145.65 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Hepatopulmonary Syndrome | Endothelin-1 (P05305) | Biliary cirrhosis in the rat triggers intrapulmonary vasodilatation and gas exchange abnormalities that characterize the hepatopulmonary syndrome This vasodilatation correlates with increased levels of pulmonary microcirculatory endothelial nitric oxide synthase (eNOS) and hepatic and plasma endothelin-1 (ET-1) [ ADR Type 2 ] | Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome |
| Hepatopulmonary Syndrome | Nitric-oxide synthase endothelial (P29474) | Biliary cirrhosis in the rat triggers intrapulmonary vasodilatation and gas exchange abnormalities that characterize the hepatopulmonary syndrome. This vasodilatation correlates with increased levels of pulmonary microcirculatory endothelial nitric oxide synthase (eNOS) and hepatic and plasma endothelin-1 (ET-1). [ ADR Type 2 ] | Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome |
| Liver Injury | Bile salt export pump (O95342) | Bosentan-induced liver injury is mediated, at least in part, by inhibition of Bsep/BSEP-causing intracellular accumulation of cytotoxic bile salts and bile salt induced liver cell damage [ ADR Type 2 ] | The endothelin antaGOnist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category